“`html
New data reveal a dramatic shift in the fight against respiratory syncytial virus (RSV), with widespread vaccination proving remarkably effective in protecting vulnerable populations. A surge in studies throughout 2025 highlighted the significant benefits of immunization for older adults, infants, and newborns-a welcome growth after decades of searching for reliable RSV defenses.
Here’s a quick look at the top RSV stories of the year.
- RSV vaccination in adults 60+ could prevent over 700,000 cases of lower respiratory tract disease and 6,000 deaths over five years.
- Nirsevimab substantially reduced RSV-related hospitalizations in infants, with a 77% lower risk observed in vaccinated babies.
- The 2024-2025 RSV season saw substantially lower hospitalization rates for infants compared to pre-pandemic levels, thanks to maternal vaccines and nirsevimab.
- Both nirsevimab and the RSVpreF vaccine demonstrated high uptake among eligible infants and pregnant individuals.
- The FDA approved clesrovimab in June, providing a second preventative option for infants during their first RSV season.
What’s the biggest takeaway from the latest RSV research? vaccination and preventative antibody treatments are proving to be highly effective in reducing severe illness and hospitalization rates across all age groups, offering a new level of protection against this common respiratory virus.
Vaccination Could Save Thousands of Older Adults
Table of Contents
A study published in October underscored the potential of RSV vaccination to dramatically reduce the burden of disease in adults aged 60 and older. Researchers utilized a complex model to estimate the public health impact of the adjuvanted RSVPreF3 vaccine over a five-year period, from August 2023 through July 2028. Their findings suggest that vaccinating 13.4 million older U.S. adults could prevent more than 700,000 cases of RSV-related lower respiratory tract disease (LRTD) and 6,025 deaths. Recommendations were updated in June 2024 to suggest a single dose of an approved RSV vaccine for adults 75 years and older, and those aged 60 to 74 years at increased risk for severe disease.
Real-World Data Backs Nirsevimab’s Effectiveness
Nirsevimab (beyfortus; Sanofi),a long-acting monoclonal antibody,continues to demonstrate its value in preventing RSV-associated hospitalization in infants. An analysis of data from 409,723 infants born between February 1, 2024, and January 31, 2025, revealed a significant difference in hospitalization rates between vaccinated and unvaccinated infants. Just 0.4% of infants who received nirsevimab were hospitalized, compared to 1.2% of those who did not. This translated to a 71% and 77% lower risk of RSV-associated hospitalization, as measured by unadjusted and adjusted hazard ratios of 0.29 and 0.23, respectively.
Infant Hospitalization Rates Plummet
The 2024-2025 RSV season witnessed a significant decline in infant hospitalization rates compared to pre-COVID-19 pandemic seasons, according to data
